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Abstract
Background: Pulmonary function measures obtained by spirometry are used to diagnose chronic obstructive
pulmonary disease (COPD) and are highly heritable. We conducted genome-wide association (GWA) analyses
(Affymetrix 100 K SNP GeneChip) for measures of lung function in the Framingham Heart Study.
Methods: Ten spirometry phenotypes including percent of predicted measures, mean spirometry measures over two
examinations, and rates of change based on forced expiratory volume in one second (FEV1), forced vital capacity (FVC),
forced expiratory flow from the 25th to 75th percentile (FEF25–75), the FEV1/FVC ratio, and the FEF25–75/FVC ratio were
examined. Percent predicted phenotypes were created using each participant's latest exam with spirometry. Predicted
lung function was estimated using models defined in the set of healthy never-smokers, and standardized residuals of
percent predicted measures were created adjusting for smoking status, pack-years, and body mass index (BMI). All
modeling was performed stratified by sex and cohort. Mean spirometry phenotypes were created using data from two
examinations and adjusting for age, BMI, height, smoking and pack-years. Change in pulmonary function over time was
studied using two to four examinations with spirometry to calculate slopes, which were then adjusted for age, height,
smoking and pack-years.
Results: Analyses were restricted to 70,987 autosomal SNPs with minor allele frequency ≥ 10%, genotype call rate ≥
80%, and Hardy-Weinberg equilibrium p-value ≥ 0.001. A SNP in the interleukin 6 receptor (IL6R) on chromosome 1
was among the best results for percent predicted FEF25–75. A non-synonymous coding SNP in glutathione S-transferase
omega 2 (GSTO2) on chromosome 10 had top-ranked results studying the mean FEV1 and FVC measurements from two
examinations. SNPs nearby the SOD3 and vitamin D binding protein genes, candidate genes for COPD, exhibited
association to percent predicted phenotypes.
Conclusion: GSTO2 and IL6R are credible candidate genes for association to pulmonary function identified by GWA.
These and other observed associations warrant replication studies. This resource of GWA results for pulmonary
function measures is publicly available at http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?id=phs000007.
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Chronic obstructive pulmonary disease (COPD), which
affects approximately six percent of the adult US popula-
tion [1] and is the fourth most common cause of death in
the US [2], has been defined as "airflow limitation that is
not fully reversible" [3], a definition based on spirometry.
Environmental factors, most notably tobacco smoking,
are associated with accelerated longitudinal decline of
pulmonary function and are important causes of COPD.
Several lines of evidence indicate that genetic factors also
contribute to the development of this condition. First,
family studies have revealed increased risk of lung func-
tion impairment in smoking first degree relatives of
COPD cases [4] and substantial heritability of spirometry
measures in population based studies [5]. Second, severe
alpha-1-antitrypsin deficiency due to homozygous muta-
tions of the SERPINA1 (AAT) gene is a documented cause
of COPD, although this condition explains only a small
proportion of COPD in the population. Finally, family-
based and case-control studies are beginning to reveal
genetic variants other than those of the SERPINA1 gene
that are associated with chronic airflow obstruction [6].
Despite this evidence of a genetic basis for susceptibility to
COPD, the specific genetic risk factors underlying most
cases of COPD remain uncertain.
The Framingham Heart Study offers the opportunity to
conduct family-based linkage and association studies
seeking potential genetic factors that influence obstructive
(COPD, asthma), restrictive, or developmentally related
lung function impairment. Using spirometry measure-
ments as quantitative phenotypes, we have previously
reported results of genome-wide linkage analyses among
these same families using microsatellite markers spaced
approximately 10 centiMorgans apart [7] and fine-map-
ping of a promising region on chromosome 6q [8,9]. The
availability of data on over 100,000 single nucleotide pol-
ymorphisms (SNPs) throughout the genome now permits
the application of genome-wide association (GWA) test-
ing to the search for genetic risk factors for chronic airflow
limitation. The longitudinal pulmonary function data
that have been obtained over the years of the Framingham
Heart Study, in combination with the 100 K SNP data,
make this a unique resource for the discovery of novel
genetic risk factors for chronic airflow obstruction.
Methods
Three types of spirometry phenotypes were evaluated for
GWA: 1) measurements taken at a participant's most
recent available examination and expressed as a percent of
predicted; 2) the mean of measurements taken at two
specified examinations; and 3) the annual rate of decline
of spirometry measurements derived by calculating the
slope of measurements across multiple examinations. All
spirometry was performed without bronchodilator test-
ing.
Measurements as percent of predicted at latest 
examination
The spirometry measurements from each participant's lat-
est examination with acceptable pulmonary function data
[10] were used; eligible examinations included Cohort
exams 19, 17, and 13 and Offspring exams 7, 6, 5, and 3.
Predicted values for each lung function measurement
were calculated using cohort and gender-specific regres-
sion models predicting spirometry measurements on the
basis of age, age squared, and height squared [11] among
Framingham subjects who were lifetime nonsmokers and
had no history of chronic bronchitis, pulmonary disease,
COPD/emphysema, asthma, or wheezing. The percent of
predicted value was calculated by dividing the observed
by the predicted value. Standardized residuals were then
created by regressing the percent predicted on current
smoking (y/n), former smoking (y/n), pack-years, and
body mass index (BMI: kg/m2), in cohort and gender-spe-
cific models. Forced expiratory volume in one second
(FEV1), forced vital capacity (FVC), forced expiratory flow
between the 25th and 75th percentile (FEF25–75), the FEV1/
FVC ratio, and the FEF25–75/FVC ratio were examined as
cross-sectional percent of predicted measures. These phe-
notypes are referenced in tables preceded by the letters
"pp" (for percent predicted), see Table 1 for explanation
of phenotype abbreviations.
Mean of measurements at two specified examinations
In previous analyses of the genetics of lung function in the
Framingham families [7,8], we have used the mean of the
values of each spirometry measure from two specified
examinations. For Cohort participants, spirometry data
from exam cycles 5 or 6 and cycle 13 were used to generate
the mean value. In Offspring participants, spirometry data
from cycle 3 and cycle 5 were used to generate the mean
value. The mean FEV1, FVC, and FEV1/FVC ratio were
adjusted for the effects of age, age2, BMI, height, dummy
variables indicating never, former, or current smoking sta-
tus, and, for former and current smokers, pack-years.
Standardized residuals were generated separately by sex
and within Cohort or Offspring samples. These pheno-
types are referenced in tables as meanfev1, meanfvc, and
meanratio.
Annual rate of decline of measurements
Rate of decline phenotypes were defined by fitting a slope
to the spirometry data from different time points. The
examinations incorporated were the same as those eligible
for percent of predicted phenotypes described above.
Slopes were calculated by ordinary least-squares using all
available data. A minimum of two eligible exams were
needed to calculate a slope. Slopes were adjusted for thePage 2 of 10
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using mean ages and heights from included exams. Slopes
were also adjusted for pack-years at first exam, interim
pack-years, and sustained smoking (y/n). FEV1 and FEF25–
75, the slope phenotypes with the highest heritability,
were studied in the GWA. These phenotypes are refer-
enced in tables as fev1slope and fefslope.
Statistical analysis methods
All SNPs were studied using family-based association tests
(FBAT) and generalized estimating equations (GEE) [12]
(see 100 K Overview). SNP results reported met the crite-
ria of having a minor allele frequency ≥10%, a Hardy-
Weinberg p-value ≥ 0.001, and a call rate ≥ 80%. All
reported FBAT tests also required a minimum of ten
informative families.
Multipoint variance component linkage analysis was
implemented with a subset of 10,588 SNPs and all 612
available microsatellites studied in previous linkage anal-
yses [12]. Multipoint identity-by-descent estimates were
generated using the software Merlin [13]. Heritability esti-
mates, estimating the proportion of the total phenotypic
variance due to genetic effects, and variance component
linkage analysis were performed using the software
SOLAR [14].
In addition to evaluating all SNP associations with each
phenotype individually, we developed a method to iden-
tify SNPs in or near genes that exhibited the strongest
associations (as assessed by p-value) to multiple spirome-
try phenotypes. For each phenotype, we identified the 200
lowest p-values that met the criteria above and were local-
ized within 60,000 base pairs of the transcription start or
stop of a gene. All gene annotations are derived from the
UCSC genome browser May 2004 assembly, build 125
http://genome.ucsc.edu/[15,16]. We evaluated the fre-
quency that a SNP appeared among the 200 lowest p-val-
ues in gene regions for the ten phenotypes. This strategy
was based on the hypothesis that SNPs identified to be
associated with multiple spirometry measures are more
likely to reflect a true association with lung function than
SNPs identified to be associated with only a single meas-
urement. SNPs in gene regions that appeared among the
lowest 200 p-values in five or more of the phenotypes
studied are reported.
Candidate genes
Genes previously reported in the literature to be associ-
ated with spirometry measures or pulmonary disease were
examined to determine whether any available 100 K SNPs
in or near the genes were associated with spirometry phe-
notypes. Twelve COPD candidate genes studied in the
Boston Early-Onset COPD cohort [17], and the SERPINE2
gene, a novel gene identified through linkage and associ-
ation with COPD in the same cohort [6], were reviewed.
The previously established COPD gene alpha-1-antit-
rypsin (SERPINA1) and the cystic fibrosis transmembrane
conductance regulator (CFTR) as well as additional genes
in the class of Glutathione S-transferases (O1, O2, M2, T1,
T2) and surfactant proteins (SFTPA1, SFTPC) were
reviewed. In addition, extracellular super oxide dismutase
(SOD3) [18,19], interleukin-8 receptor alpha (IL8RA)
[20], interleukin-10 (IL10) [21], beta-2 adrenergic recep-
tor (ADRB2) [22], and transforming growth factor beta-1
(TGFB1) [23] were examined as COPD candidates. The
GEE and FBAT SNP association results in or within 60
kilobase pairs (kb) of these 27 genes was reviewed. By
specifying a 60 kb distance around the gene to screen
results, we were able to identify SNPs near most candidate
Table 1: Characteristics of phenotypes studied*
Eligible exam cycles
Phenotype Na Description Offspring Cohort Adjustmentb Heritability
ppfev1 1217 Percent predicted FEV1 for latest exam 7, 6, 5, 3 19, 17, 13 Predicted defined by age, age2, height, % 
predicted adjusted for current or former 
smoking, pack-years, and BMI
0.36
ppfvc 1217 Percent predicted FVC for latest exam 7, 6, 5, 3 19, 17, 13 Same as ppfev1 0.45
ppratio 1217 Percent predicted FEV1/FVC for latest 
exam
7, 6, 5, 3 19, 17, 13 Same as ppfev1 0.29
ppfef 1212 Percent predicted FEF25–75 for latest exam 7, 6, 5, 3 19, 17, 13 Same as ppfev1 0.40
ppfefrat 1212 Percent predicted FEF25–75/FVC for latest 
exam
7, 6, 5, 3 19, 17, 13 Same as ppfev1 0.41
meanfev1 1222 Mean FEV1 from two exams 3 and 5 5 or 6 and 13 age, age2, BMI, height, current or former 
smoking, and pack-years
0.35
meanfvc 1222 Mean FVC from two exams 3 and 5 5 or 6 and 13 Same as meanfev1 0.51
meanratio 1222 Mean FEV1/FVC from two exams 3 and 5 5 or 6 and 13 Same as meanfev1 0.25
fev1slope 1097 Longitudinal slope of FEV1 7, 6, 5, 3 19, 17, 13 age, age2, height, height2, pack-years at first 
exam, interim pack-years, and sustained 
smoking
0.10
fefslope 1059 Longitudinal slope of FEV25–75 7, 6, 5, 3 19, 17, 13 Same as fev1slope 0.20
*Results for additional longitudinal slope phenotypes, residual from predicted phenotypes, phenotypes created from spirometry at a single exam, and phenotypes limited to 
smokers reporting 10 or more pack-years are available at http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?id=phs000007
a) sample size with phenotype out of 1345 with GWA genotyping
b) adjustment performed in four separate regression models by sex and Original or Offspring cohortPage 3 of 10
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strictly within the transcription start or stop of the gene of
interest.
Results
Table 1 reports the heritability estimates for each of the
ten phenotypes presented. The slope phenotypes have
lower heritability than their corresponding cross sectional
phenotypes. FVC has the highest heritability among phe-
notypes defined using the same method (percent pre-
dicted or mean). The percent predicted FEF25–75/FVC ratio
had a higher heritability estimate than either FEV1/FVC
ratio phenotype.
Table 2 reports the SNPs with the lowest p-values for any
of the 10 phenotypes evaluated in GWA analysis. Results
were ranked by p-value and the top 25 SNPs are reported.
In some cases, a SNP had top ranked results for multiple
correlated phenotypes, and thus the p-value for all pheno-
types is reported at the ranking position of the best p-
value. Table 2a was ranked by GEE p-value, and Table 2b
was ranked by FBAT p-value. SNP positions are reported
according to NCBI Human Genome Build 35. SNPs in the
Affymetrix set whose chromosome and position are
unknown and SNPs on sex chromosomes are not reported
for association. In total, 70,987 SNPs were considered in
association analyses. None of these results achieved a con-
servative threshold for genome-wide significance. All
results, regardless of allele frequency, call rate, or devia-
tion from Hardy-Weinberg are publicly available at http:/
/www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/
study.cgi?id=phs000007.
Only a single SNP among those reported in Tables 2a and
2b is a known coding SNP. Among the top ranked GEE p-
values was a non-synonymous coding SNP (rs156697) in
the Glutathione S-transferase omega 2 gene (GSTO2) on
chromosome 10. The SNP was among the top ranked GEE
p-values for association with the mean FEV1 and mean
FVC phenotypes.
Other SNPs reported in Table 2a were localized to intronic
gene regions in COL1A2, ADARB1, SNTG1, RHBDD1,
NID2, IL6R, and SYT10. The best GEE p-value localized to
the untranslated region of SNRPN. SNPs identified by
FBAT p-value, reported in Table 2b, located in introns
were in CCBL2, LRRC9, PAX3, LIPF, MTHFD1L, and
KIAA1797. Additional genes reported in Tables 2a and 2b
were within 60 kb of the associated SNP. SNP rs2906966,
among the top 25 p-values for both tests, is located near
CDRT4. SNPs reported may be in linkage disequilibrium
(LD). Among the top six FBAT results, strong LD was
observed between the three chromosome 1 SNPs in
CCBL2, and the three chromosome 14 SNPs in LRRC9,
thus only 2 regions are being identified.
Linkage to all autosomes and the X chromosome was per-
formed. Table 2c reports all LOD scores above 2.0 with
the 1.5-LOD support interval. The best LOD score
observed is in a region of linkage on chromosome 6q that
was reported previously using microsatellites in the Fram-
ingham families [7,8]. The original LOD score of 2.4 for
mean FEV1 using genome-wide microsatellites [7] was
increased to a LOD of 2.89 with the addition of SNP data,
and a LOD of 2.65 was observed in the same region for the
percent predicted FEV1 phenotype. The second highest
LOD score observed was 2.86 for the longitudinal FEF25–
75 phenotype, which was located on the X chromosome.
The percent predicted FEV1 and FVC phenotypes both had
LOD scores over 2.0 on chromosome 4, with overlapping
LOD support intervals centered around 166–170 Mb.
Table 3 reports SNPs that met the quality control criteria
and were among the top 200 p-values for SNPs located
within 60 kb of a gene for at least five of the phenotypes
studied. A SNP in an intron of the interleukin 6 receptor
(IL6R) and a SNP near the sodium channel, voltage gated,
type I alpha (SCN1A) gene were among the top ranked
result for six phenotypes. All others were among the top
ranked results for five phenotypes. The genes syntrophin,
gamma 1 (SNTG1) and the chromosome 20 open reading
frame 133 (C20orf133) appear in both the FBAT and GEE
lists of top results across 5 phenotypes. The two SNPs in
SNTG1 are separated by 104 kb and have low LD (r2 =
0.05 and D' = 0.28 in the HapMap CEU sample). The two
C20orf133 SNPs are in strong LD (r2 = 0.78 in HapMap
CEU), though rs10485771 is located 3' of the gene.
Table 4 reports the best p-value observed when examining
SNP results specifically in the regions of the 27 candidate
genes. SNPs reported are within 60 kb of the transcription
start or stop for the gene listed, and sometimes lie within
a different gene. Only 20 of the 27 genes of interest had
SNPs in or within 60 kb of the gene. No SNPs were near
enough to the genes GSTM1 and TNF, presented by Hersh
et al. (2005), and GSTO1, GSTT1, SFTPA1, SFTPC and
IL8RA to be considered. Of the 20 best FBAT results, 12
were p-values less than 0.05, but only 5 were p-values less
than 0.01. Of the best GEE results, 14 were p-values less
than 0.05, and 5 were p-values less than 0.01. Three gene
regions had p-values less than 0.01 for both types of test,
and these were CFTR, GSTO2, and SOD3. The vitamin D
binding protein (GC) region produced an FBAT p-value of
0.0009, though GEE results were weaker.
Discussion
This is the first GWA of quantitative lung function meas-
ures to be reported, and it provides an opportunity for
both hypothesis generation and hypothesis testing. We
have identified a number of novel gene regions associated
with pulmonary function. Associations with these SNPsPage 4 of 10
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2a Top Association results based on GEE p-value
Phenotype SNP Chr Physical 
position
GEE p-value FBAT p-value Gene Region
fev1slope 1. rs3867498 15 22629880 1.36 × 10-06 0.07 SNRPN
meanfvc 2. rs441051 7 93698651 2.16 × 10-06 0.005 COL1A2
meanratio 3. rs2838815 21 45454018 2.63 × 10-06 0.0002 ADARB1
ppfvc 4. rs1455782 15 90851970 4.23 × 10-06 0.18 FLJ32831
meanfvc 5. rs10516541 4 108472826 4.32 × 10-06 7.19 × 10-05
meanfev1 1.7 × 10-05 0.0002
ppratio 6. rs310558 8 51575144 5.14 × 10-06 0.14 SNTG1
ppfev1 7. rs3820928 2 227598971 5.33 × 10-06 0.0005 RHBDD1
ppfef 8. rs730532 14 51588561 5.89 × 10-06 0.15 NID2
ppfefrat 9. rs808225 14 57467669 7.38 × 10-06 0.0008
ppratio 1.45 × 10-05 0.007
ppfef 10. rs4129267 1 151239337 7.39 × 10-06 0.07 IL6R
ppfev1 11. rs2906966* 17 15272242 8.31 × 10-06 5.03 × 10-05 CDRT4
ppfvc 12. rs357394 7 137506642 8.77 × 10-06 0.14
fefslope 13. rs1994169 12 33436783 9.55 × 10-06 0.05 SYT10
meanratio 14. rs2225434 21 45458574 9.68 × 10-06 0.0004 ADARB1
meanfvc 15. rs156697(a) 10 106029175 9.78 × 10-06 9.42 × 10-05 
meanfev1 1.8 × 10-05 0.002 GSTO2
ppfefrat 16. rs564425 13 46797096 1.03 × 10-05 0.02
ppfef 17. rs10498441 14 51613974 1.06 × 10-05 0.28 NID2
ppratio 18. rs880713 2 128847844 1.11 × 10-05 0.26 AK128224
ppfefrat 19. rs811732 14 57456738 1.3 × 10-05 0.20
ppfvc 20. rs6558132 8 29526866 1.58 × 10-05 0.74
fev1slope 21. rs6972823 7 3009137 1.69 × 10-05 0.10
ppfef 22. rs9285611(b) 1 81895076 1.7 × 10-05 0.07
meanfev1 23. rs10504836 8 88669709 1.72 × 10-05 0.28
meanfev1 24. rs1491520 3 193243153 1.77 × 10-05 0.12
ppfvc 25. rs9300826 13 103001176 1.79 × 10-05 0.11
2b Top Association results based on FBAT p-value
Phenotype SNP Chr Physical position GEE p-value FBAT p-value Gene Region
ppratio 1. rs10922530 1 89139273 0.001 8.7 × 10-07
ppfefrat 0.002 3.78 × 10-06
ppfef 0.005 2.36 × 10-05 CCBL2
ppfefrat 2. rs3753683 1 89139592 0.004 1.87 × 10-06
ppratio 0.004 3.59 × 10-06
ppfef 0.01 1.42 × 10-05 CCBL2
ppratio 3. rs219349 14 59525168 0.01 6.15 × 10-06
ppfefrat 0.04 4.91 × 10-05 LRRC9
ppratio 4. rs219391 14 59554684 0.02 6.18 × 10-06 LRRC9
ppratio 5. rs219326 14 59512943 0.02 8.51 × 10-06Page 5 of 10
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ppfefrat 6. rs1409149 1 89141170 0.005 9.12 × 10-06
ppratio 0.005 1.08 × 10-05
ppfef 0.01 5.14 × 10-05 CCBL2
ppfvc 7. rs9299191 9 110944100 0.009 1.79 × 10-05
meanfvc 8. rs10515289(c) 5 99315845 0.17 2.21 × 10-05
ppfvc 9. rs10498137 2 222966943 0.05 2.23 × 10-05 PAX3
ppfef 10. rs3858282 10 90424391 0.001 2.92 × 10-05 LIPF
ppratio 11. rs905367 4 59896363 0.02 2.95 × 10-05
meanfvc 12. rs10495872 2 37915266 0.05 3.02 × 10-05
fev1slope 13. rs1347222 12 80896622 0.01 3.27 × 10-05
ppratio 14. rs2009488 4 59895895 0.03 3.43 × 10-05
meanfvc 15. rs6481257 10 58608558 0.02 3.52 × 10-05
ppratio 16. rs461951 14 59608986 0.02 3.63 × 10-05 LRRC9
meanfev1 17. rs491552 6 151403169 0.01 3.86 × 10-05 MTHFD1L
meanfev1 18. rs1910137 4 27087329 0.08 4.04 × 10-05
ppfvc 19. rs2831605(d) 21 28467064 0.03 4.41 × 10-05
ppfev1 20. rs2906966* 17 15272242 8.31 × 10-06 5.03 × 10-05 CDRT4
fefslope 21. rs6740919 2 67531706 0.0009 5.17 × 10-05 ETAA16
meanfev1 22. rs10498818 6 63134129 0.02 5.25 × 10-05
ppfefrat 23. rs1393593 4 59907689 0.06 5.44 × 10-05
ppfefrat 24. rs9312080 4 59891451 0.11 5.63 × 10-05
ppfefrat 25. rs7851363 9 20748306 0.006 5.7 × 10-05 KIAA1797
2c Linkage peaks with LOD score > 2.0
Phenotype SNP Chr Physical position 1.5-LOD interval 
start
1.5-LOD interval 
end
LOD score
meanfev1 rs2300081 6 168097526 165513097 170788550 2.89
fefslope rs5909594 X(e) 118057198 113970434 124311695 2.86
ppfev1 AGC001b 6 170788550 164268152 170788550 2.65
ppratio rs10497042 2 150675813 148296793 154203261 2.40
meanratio rs10518669 1 82811739 74999965 88728520(b) 2.37
ppfef rs2974490 5 113433775 95608129 124687730(c) 2.29
meanfvc rs10488908 21 21904704 19805361 34461762(d) 2.29
ppfev1 rs10518032 4 170322764 161768472 181501690 2.28
ppfvc rs10489542 1 225169260 213625196 233478438 2.17
ppfef rs721411 17 36902470 28313357 52519635 2.17
ppfev1 rs753765 17 57323782 45345729 59677087 2.17
meanfev1 rs4918762 10 114389096 102080914 122214789(a) 2.12
ppfvc rs10517825 4 166251091 156507719 191091333 2.02
*) SNP occurring in both Table 2a and 2b
a) SNP associated to meanfvc and meanfev1 in Table 2a under linkage peak for meanfev1 on chromosome 10.
b) SNP associated to ppfef in Table 2a under linkage peak for meanratio on chromosome 1.
c) SNP associated to meanfvc in Table 2b under linkage peak for ppfef on chromosome 5.
d) SNP associated to ppfvc in Table 2b under linkage peak for meanfvc on chromosome 21.
e) X chromosome linkage results are not available online
Table 2: GEE, FBAT, and linkage results (Continued)Page 6 of 10
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ples as well as functional studies before any statement
about causality is warranted. Many of the best p-values are
likely to reflect false positive results, and GEE results
exhibited elevated Type I error [12] (see 100 K Overview).
Additional studies of this data will be useful, including
smoking stratified analyses and more sophisticated
approaches to creating multivariate phenotypes. How-
ever, several of the observed associations involve genes for
which there are plausible biologic rationales for a relation
to lung function phenotypes.
The Glutathione S-Transferase (GST) superfamily genes
are of interest because of their role in metabolism of xeno-
biotics, such as cigarette smoke. Recently, Hersh et al.
studied GSTP1 and GSTM1 in two independent analyses
of COPD and reported null findings. In contrast, a study
of annual change in lung function measures in a popula-
tion based cohort reported that the GSTT1 deletion alone
or in combination with the GSTM1 deletion influenced
decline in FEV1 in men [24]. Using the Affymetrix 100 K
SNP GeneChip, we have limited ability to directly confirm
or refute the aforementioned findings because no SNPs
were genotyped within 10 kb of the genes.
Here, we show that a non-synonymous SNP in exon 5 of
GSTO2 encoding an Asn142Asp amino acid change is
among the most striking GWA results for mean FEV1 and
FVC phenotypes. Both the non-synonymous SNP,
rs156697, and a second SNP, rs156699, located in an
intron exhibited strong association using both FBAT and
GEE tests (r2 between SNPs = 0.8 in HapMap CEU). Link-
age results also support the evidence for GSTO2, as the
gene's position lies within the confidence interval around
the LOD of 2.12 observed on chromosome 10 for mean
FEV1 (Table 2c). GSTO2 is involved in the biotransforma-
tion of arsenic, which is a component of cigarette smoke,
and may exhibit modest expression in bronchial epithe-
lial cells. Gene expression studies in COS-1 cells demon-
strated that the Asp142 variant exhibited 76% of the level
of expressed protein occurring in the wild-type, and
expression levels were further reduced to 15% when the
Asp142 occurred in conjunction with an Ile158 variant
[25]. The observation of strong association to a non-syn-
onymous polymorphism with demonstrated effects on
gene expression is compelling. Moreover, this finding in
conjunction with a growing literature on GST gene associ-
ation with pulmonary phenotypes suggests that a com-
plete evaluation of functional variants in this gene family
may be warranted.
The IL6R SNP was not only among the top 25 p-values for
percent predicted FEF25–75, but also among the top 200 p-
values in gene regions for six of the ten phenotypes pre-
sented. IL6R is thought to be expressed in lung, and may
play a role in the immune response. Recently, we have
shown that IL6 levels in blood were associated with
impaired lung function in the Framingham offspring
cohort [26]. The IL6 pathway, as a mediator of the inflam-
matory process, is of interest as it relates to lung function
phenotypes.
The SNP identified in the SOD3 region lies within a hypo-
thetical protein 3' of the SOD3 gene. The non-synony-
mous SNP in SOD3 that has been reported for association
with COPD (rs1799895) was not included in the Hap-
Map, so we could not determine the extent of LD between
it and the SNPs genotyped in this study. Another exon 3
SNP (rs2536512) located 519 base pairs away from
rs1799895 is present in the HapMap. The associated SNP
identified in this study, rs10489030, is in very low LD
with the SOD3 exon 3 HapMap SNP (D' = 0.32 and r2 =
Table 3: Top ranked SNPs within 60 kb of a gene and associated with five or more of the phenotypes studied
SNP Chr bp position Gene region
3a GEE
rs4129267 1 151239337 IL6R
rs7587026 2 166804257 SCN1A
rs3820928 2 227598971 RHBDD1
rs445347 5 53011487 NDUFS4
rs310558 8 51575144 SNTG1
rs581446 18 10646848 FAM38B
rs10485770 20 13943214 C20orf133
3b FBAT
rs10489030 4 24521105 3' of SOD3
rs2438345 5 90198041 GPR98
rs7759033 6 116404207 FRK
rs2391996 7 31487207 C7orf16
rs10504106 8 51471079 SNTG1
rs10485771 20 13999103 C20orf133Page 7 of 10
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exonic SNP and this 3' SNP, separated by 43.5 kb, does
not suggest a clear replication of association with the
SOD3 gene, but suggests that the genomic region is of
continued interest. Also on chromosome 4, a SNP in the
region of the vitamin D binding protein (GC) was associ-
ated with the percent predicted FEF25–75/FVC ratio with a
p-value of 0.0009 using the FBAT test, but this SNP is in
low LD with the Asp432Gly polymorphism, rs7041 (D' =
0.17 and r2 = 0.007 in HapMap CEU).
The SNP identified in the region of SERPINE2 (rs717610)
was not in LD with the six reported SNPs replicating sig-
nificant associations to COPD [6] that were also available
in HapMap, as the r2 values ranged from 0.002 to 0.008.
Two of the top SNPs (rs3820928, GEE rank #7;
rs10498137, FBAT rank #9) lie within the linkage region
identified for FEV1/FVC in severe early-onset COPD cases
[27] that subsequently led to the discovery of the
SERPINE2 associated SNP. SNP rs3820928 was among
those identified with association to five of the phenotypes
studied and lies in the gene RHBDD1 (alias
DKFZp547E052). Not much is known about the function
of this gene, but the associated SNP is located in a region
with LD extending to the adjacent COL4A4 gene. The
rs3820928 exhibited an r2 of 0.81 with two non-synony-
mous coding SNPs in COL4A4 in the HapMap CEU data.
Defects in Type IV collagen genes have been shown to
Table 4: Candidate gene evaluation
Gene region Chr SNP Phenotype FBAT p-value GEE p-value
Alpha-1-antitrypsin (AAT/SERPINA1) 14 rs2402446 ppfvc
fev1slope
0.02 0.30
rs10484042 0.90 0.01
Beta-2 adrenergic receptor (ADRB2) 5 rs30329 fefslope
meanratio
0.009 0.07
rs9325117 - 0.04
cystic fibrosis transmembrane regulator (CFTR) 7 rs213987 meanfvc
ppratio
0.006 0.38
rs10487367 0.25 0.002
Microsomal epoxide hydrolase (EPHX1) 1 rs3738051 fefslope
ppfefrat
0.01
0.03
0.30
0.04
Vitamin D binding protein (GC) 4 rs423817 ppfefrat
ppfefrat
0.0009 0.06
rs842873 0.05 0.02
Glutathione S-transferase M2 (GSTM2) 1 rs542338 meanratio
fev1slope
0.19
0.43
0.63
0.20
Glutathione S-transferase O2 (GSTO2) 10 rs156697 meanfvc 9.4 × 10-05 9.8 × 10-06
Glutathione S-transferase P1 (GSTP1) 11 rs688878 ppfefrat
ppfvc
0.07
0.39
0.35
0.02
Glutathione S-transferase T2 (GSTT2) 22 rs140289 ppfvc
ppfev1
0.17
0.41
0.13
0.10
Heme oxygenase (HMOX1) 22 rs2267331 fev1slope
meanratio
0.07 0.80
rs10483190 0.82 0.008
Interleukin-10 (IL10) 1 rs10494879 fefslope
fev1slope
0.06
0.46
0.73
0.02
Matrix metalloproteinase-1 (MMP1) 11 rs495366 fefslope
ppfef
0.02
0.20
0.13
0.03
Matrix metalloproteinase-9 (MMP9) 20 rs2903908 ppfefrat 0.19 0.05
Alpha-1-antichymotrypsin (SERPINA3) 14 rs10484047 ppfvc
fev1slope
0.02
0.10
0.03
0.01
Serine proteinase inhibitor E2 (SERPINE2) 2 rs717610 meanfvc
meanratio
0.04
0.19
0.003
0.001
Surfactant protein B (SFTPB) 2 rs7577293 meanratio 0.02 0.06
Surfactant protein D (SFTPD) 10 rs726289 fefslope 0.02 0.03
extracellular super oxide dismutase (SOD3) 4 rs10489030 ppfev1
ppfvc
0.0005
0.01
0.02
0.007
transforming growth factor beta-1 (TGFB1) 19 rs3745295 fev1slope
ppfev1
0.21
0.74
0.62
0.18
Tissue inhibitor of metalloproteases-2 (TIMP2) 17 rs2889529 ppfef
meanratio
0.07
0.18
0.11
0.09
Best p-value for FBAT and GEE tests reported with specific SNP*phenotype producing result. P-values < 0.01 bolded.Page 8 of 10
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ease affecting the lung [28], and both COL4A4 and
COL4A3 lie in this region, sharing a common promoter.
These results do not provide a strong replication of the
original SERPINE2 SNP associations due to the low LD
between SNPs reported in the literature and the SNPs
from the 100 K data with association. However, the results
suggest that chromosome 2q is of continued interest and
may harbor multiple genes influencing lung function.
Studying lung function measures in a community-based
sample may identify genetic variants associated with lung
growth and development, susceptibility to obstructive
ventilatory impairment related to asthma, emphysema
and COPD or susceptibility to restrictive ventilatory
impairment due to pulmonary fibrosis or other processes.
The relevance to disease pathogenesis of associations
between SNPs and lung function must be interpreted with
caution, and some of the observed associations may
reflect polymorphisms that protect against ventilatory
impairment by leading to better lung function in early life
or protection against the adverse effects of cigarette smok-
ing. All of the GWA results are publicly available at http:/
/www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/
study.cgi?id=phs000007. Replication of novel results
identified by GWA will be the true test of the value of the
GWA approach to gene discovery.
Conclusion
These publicly available results provide a resource for
investigators to assess whether their findings of associa-
tion to pulmonary function phenotypes replicate in the
Framingham population. In addition, we have identified
novel results that warrant replication studies in other pop-
ulations.
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